

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of December 16, 2004


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (currently amended) A compound of formula (I)




wherein X is O; R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, -CN, -SR⁶, -S(O)₂R⁶; or heterocycle, optionally substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl, -CN, and C₆₋₁₄arylC₁₋₈alkyl; R⁶ is C₁₋₈alkyl, optionally substituted with halogen; R⁷ is C₁₋₈alkyl optionally substituted with ~~one or more substituents selected from the group consisting of~~ hydroxy; -NH₂; or heterocycle; R² is hydrogen; R³ is hydrogen or C₁₋₈alkyl; R⁴ is heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, C₁₋₈alkyl, -OR¹¹ and -SR¹⁰N(R¹⁰)₂, S(O)₂NR⁸R⁹; or C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of hydroxy, halogen, -CF₃, C₁₋₈alkyl, hydroxyC₁₋₈alkyl, -CN, -NO₂, -C(O)NH₂, -S(O)R⁷, -S(O)₂R⁷, -S(O)₂NR⁸R⁹, -OR¹¹, -C(O)NR¹¹, -C(O)OR¹¹, -NR¹¹, -NC(O)R¹¹, and heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C₁₋₈alkyl and heterocycleC₁₋₈alkyl; R⁸ and R⁹ are the same or different and are selected from the group consisting of hydrogen, C₁₋₈alkyl, C₁₋₈alkylheterocycle, heterocycle, and C₃₋₆cycloalkyl; R¹⁰ is C₁₋₈alkyl; R¹¹ is C₁₋₈alkyl, optionally substituted with -SO₂NR⁸R⁹; and R⁵ is halogen or -NO₂; or a pharmaceutically acceptable salt thereof.

Claim 3 (previously presented) A compound of formula (I)

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of December 16, 2004


alkyl, -NO₂, -NH₂, C₁₋₈alkylamino, CF₃, or alkoxy; or a pharmaceutically acceptable salt thereof.

Claim 5 (previously presented) A compound of formula (I)



wherein X is O, R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, and -CN; R² and R³ are hydrogen; R⁴ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, C₁₋₈alkyl, -CN, -NO₂, -S(O)R⁷, -S(O)₂R⁷, -NS(O)₂R⁷, wherein R⁷ is -NH₂; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 6 (previously presented) A compound of formula (IA)



wherein:

X is C, O, or N;

Serial No. 10/070,084
Docket No. PU35171/Sw
Reply to Office Action of December 16, 2004

R¹ is C₆₋₁₄aryl which may be optionally substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, C₁₋₈alkylamino, alkoxy, C₃₋₆cycloalkyl, C₂₋₆alkenyl, C₆₋₁₄arylC₂₋₆alkenyl, -CN, -NO₂, -NH₂, -SR⁶, -S(O)₂R⁶, -S(O)R⁷, -S(O)₂R⁷, -C(O)R⁷, C₂₋₆alkenyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, and heterocycle and C₂₋₆alkynyl which may be optionally substituted with a substituent selected from the group consisting of hydroxy, halogen, aryl, C₃₋₆cycloalkyl, and heterocycle;

R⁶ is C₁₋₈alkyl optionally substituted with one or more substituents selected from the group consisting of hydroxyl, halogen, -CF₃, aryl, and heterocycle;

R⁷ is C₁₋₈ alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, aryl, C₃₋₆cycloalkyl and heterocycle; -NH₂; or heterocycle;

R² is hydrogen, halogen, or C₁₋₈alkyl;

R³ is hydrogen;

R⁴ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of hydroxy, halogen, -CF₃, C₁₋₈alkyl, hydroxycycloalkyl, -CN, -NO₂, C₁₋₈alkylamino, heterocycleC₁₋₈alkyl, -C(O)NH₂, -S(O)R⁷, -S(O)₂R⁷, -C(O)R⁷, -NS(O)₂R⁷, -S(O)₂NR⁸R⁹, -S(O)₂NHR¹¹, -S(O)₂R¹¹, -S(O)₂NR⁷COR¹¹, -S(O)₂NHCOR¹¹, -S(O)₂[COR¹¹]_n wherein n is 1, 2, or 3, -OR¹¹, -OR¹¹OR¹¹, -C(O)R¹¹, -C(O)NR¹¹, -C(O)OR¹¹, -NR¹¹, -NC(O)R¹¹, heterocycleC₂₋₆alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C₁₋₈alkyl, and C(O)OR¹¹, and C₁₋₈alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with -C(O)R¹¹;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, C₃₋₆cycloalkyl, C₁₋₈alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C₆₋₁₄aryl optionally substituted with alkoxy, C₁₋₈alkylamino, C₁₋₈alkylheterocycle, heterocycle, heterocycleC₁₋₈alkyl, C₃₋₆cycloalkylC₁₋₈alkyl, and C₃₋₆cycloalkyl;


R¹¹ is C₁₋₈alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, halogen, C₁₋₈alkyl, C₃₋₆cycloalkyl, alkoxy, -S(O)₂NR⁸R⁹, NCONH₂, and heterocycle optionally substituted with one or more substituents selected from the group consisting of oxo, hydroxy, and C₁₋₈alkyl; heterocycle optionally substituted with heterocycleC₁₋₈alkyl; or C₆₋₁₄aryl optionally substituted with alkoxy;

R⁵ is hydrogen, halogen, C₁₋₈alkyl, -NO₂, -NH₂, C₁₋₈alkylamino, CF₃, or alkoxy;

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of December 16, 2004

wherein X is O; R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, and -CN; R² is hydrogen; R³ is hydrogen; R⁴ is heterocycle; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 10 (previously presented) A compound of formula (IC)



wherein:

X is C, O, or N;

R¹ is heterocycle, optionally substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl, halogen, -CN, C₆₋₁₄arylC₁₋₈alkyl and heterocycle;

R² is hydrogen, halogen, or C₁₋₈alkyl;

R³ is hydrogen;

R⁴ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of hydroxy, halogen, -CF₃, C₁₋₈alkyl, hydroxyC₁₋₈alkyl, -CN, -NO₂, C₁₋₈alkylamino, heterocycleC₁₋₈alkyl, -C(O)NH₂, -S(O)R⁷, -S(O)₂R⁷, -C(O)R⁷, -NS(O)₂R⁷, -S(O)₂NR⁸R⁹, -S(O)₂NHR¹¹, -S(O)₂R¹¹, -S(O)₂NR⁷COR¹¹, -S(O)₂NHCOR¹¹, -S(O)₂[COR¹¹]_n wherein n is 1, 2, or 3, -OR¹¹, -OR¹¹OR¹¹, -C(O)R¹¹, -C(O)NR¹¹, -C(O)OR¹¹, -NR¹¹, -NC(O)R¹¹, heterocycleC₂₋₆alkenyl, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo, C₁₋₈alkyl, and C(O)OR¹¹, and C₁₋₈alkyl which may be optionally substituted with one or more substituents selected from the group consisting of -CN and heterocycle, optionally substituted with -C(O)R¹¹;

R⁷ is C₁₋₈ alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, aryl, C₃₋₆cycloalkyl and heterocycle; -NH₂; or heterocycle;

Serial No. 10/070,084
Docket No. PU3517USw
Reply to Office Action of December 16, 2004

R² is hydrogen, halogen, or C₁₋₈alkyl;

R³ and R⁴ are independently hydrogen; hydroxy; heterocycle optionally substituted with one or more substituents selected from the group consisting of oxo, hydroxy, hydroxyC₁₋₈alkyl, halogen, C₁₋₈alkyl, -OR¹¹, -S(O)₂NR⁸R⁹, and -SR¹⁰N(R¹⁰)₂; or R³ and R⁴ together with the nitrogen atom to which they are attached form a heterocycle which may be optionally substituted with C₆₋₁₄aryl, which may be optionally substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl and -NO₂; provided that R³ and R⁴ cannot both be hydrogen or hydroxy;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, C₃₋₆cycloalkyl, C₁₋₈alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, heterocycle, CN and C₆₋₁₄aryl optionally substituted with alkoxy, C₁₋₈alkylamino, C₁₋₈alkylheterocycle, heterocycle, heterocycleC₁₋₈alkyl, C₃₋₆cycloalkylC₁₋₈alkyl, and C₃₋₆cycloalkyl;

R¹⁰ is C₁₋₈alkyl;

R¹¹ is C₁₋₈alkyl, optionally substituted with one or more substituents selected from the group consisting of hydrogen, C₁₋₈alkyl, -S(O)₂NR⁸R⁹, and heterocycle optionally substituted with one or more substituents selected from the group consisting of oxo, and C₁₋₈alkyl;

R⁵ is hydrogen, halogen, C₁₋₈alkyl, -NO₂, -NH₂, C₁₋₈alkylamino, CF₃, or alkoxy; or a pharmaceutically acceptable salt thereof.

Claim 13 (previously presented) A compound of formula (ID) according to claim 12 wherein X is O; R¹ is heterocycle; R² and R³ are hydrogen; R⁴ is heterocycle; and R⁵ is halogen; or a pharmaceutically acceptable salt thereof.

Claim 14 (previously presented) A compound according to claim 6 wherein X is O.


Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (currently amended) A compound of formula (III)

Serial No. 10/070,084
 Docket No. PU3517USw
 Reply to Office Action of December 16, 2004



wherein R¹ is C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of halogen, -CF₃, C₁₋₈alkyl, -CN, -SR⁶, -S(O)₂R⁶; or heterocycle, optionally substituted with one or more substituents selected from the group consisting of C₁₋₈alkyl, -CN, and C₆₋₁₄arylC₁₋₈alkyl; R⁶ is C₁₋₈alkyl, optionally substituted with halogen; R⁷ is C₁₋₈alkyl, optionally substituted with ~~one or more substituents selected from the group consisting of hydroxy, -NH₂, or heterocycle~~; R⁴ is heterocycle, optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, C₁₋₈alkyl, -OR¹¹ and -SR¹⁰N(R¹⁰)₂; or C₆₋₁₄aryl substituted with one or more substituents selected from the group consisting of hydroxy, -CF₃, C₁₋₈alkyl, hydroxyc₁₋₈alkyl, -CN, -NO₂, -C(O)NH₂, -S(O)₂R⁷, -S(O)₂NR⁸R⁹, -OR¹¹, -C(O)NR¹¹, -C(O)OR¹¹, -NR¹¹, -NC(O)R¹¹, heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of oxo